Abstract
A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20%), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9%), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.
| Original language | English |
|---|---|
| Pages (from-to) | 767-772 |
| Number of pages | 6 |
| Journal | Cancer |
| Volume | 52 |
| Issue number | 5 |
| State | Published - Oct 6 1983 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study. / Soloway, M. S.; Einstein, A.; Corder, M. P.; Bonney, W.; Prout, G. R.; Coombs, J.
In: Cancer, Vol. 52, No. 5, 06.10.1983, p. 767-772.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study
AU - Soloway, M. S.
AU - Einstein, A.
AU - Corder, M. P.
AU - Bonney, W.
AU - Prout, G. R.
AU - Coombs, J.
PY - 1983/10/6
Y1 - 1983/10/6
N2 - A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20%), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9%), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.
AB - A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20%), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9%), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.
UR - http://www.scopus.com/inward/record.url?scp=0020605706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020605706&partnerID=8YFLogxK
M3 - Article
C2 - 6347356
AN - SCOPUS:0020605706
VL - 52
SP - 767
EP - 772
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 5
ER -